ST. LOUIS, Dec. 16, 2011 /PRNewswire/ -- Veran Medical Technologies announced today the release of its SPiN Drive platform upgrade for bi-planar virtual fluoroscopy view used to navigate multiple planes simultaneously. This advancement is the first of its kind in pulmonology, enabling physicians to view the location of the Always-On Tip Tracked instrument in a fluoro-like view without any radiation being delivered to the patient, physician or staff.
"The significance of targeting Solitary Pulmonary Nodules (SPNs) without radiation is exciting," said Alexander C. Chen, M.D., of Washington University, St. Louis, MO. "The virtual fluoroscopic view provides images that the majority of bronchoscopists utilize while targeting solitary pulmonary nodules, without the radiation exposure. Additionally, the ability to map airways during procedures may provide a significant advantage towards targeting SPNs."
"This enhancement is ground-breaking technology," said Mark Hunter, vice president of strategic operations at Veran Medical Technologies. "Auto-rotate fly-through view makes instrument steering more intuitive and consistent with the user's standard bronchoscopic view."
Lung cancer is a deadly disease that mortally claims 85 percent of patients within five years. Diagnosing lung cancer at Stage I improves survival chances significantly. Due to the 69 million CT scans that occur annually in the United States, inadvertent lung cancer screening is occurring. However, SPNs in the peripheral lung are inaccessible with today's techniques and technologies, leaving patients on "watchful waiting" protocols of repeat CT scanning causing significant patient anxiety and unproductive costs added to the U.S. healthcare system. Veran's SPiN Drive product acts as a GPS-like system to enable pulmonologists and surgeons to access SPNs and immediately diagnose malignancy, end watchful waiting and reduce healthcare spending.
About Veran Medical Technologies, Inc.
Veran Medical Technologies is a privately held company led by a team of innovators focused on developing the next standard of care for minimally invasive delivery of interventional oncology therapies. Veran has built several clinical products upon its ig4 platform technology, which uses proprietary 4D registration capabilities for targeting lesions within the human body. The company believes that by enabling minimally invasive early stage treatments, it can increase patient survival and lower healthcare costs significantly. Veran Medical Technologies is headquartered in St. Louis, MO.
SOURCE Veran Medical Technologies